FDA clears foralumab nasal spray for expanded use in Alzheimer’s
Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s disease, and the first patient is expected to be dosed soon. An expanded use program, also called a compassionate…